About Us


Dr. Werner Braun

Having received a PhD in plasma and laser physics from the Technical University in Munich for research work performed at the Max Planck Institute for Plasma Physics, Werner initially worked for Messer Griesheim before joining BIOTRONIK as VP of Marketing and Sales.

Over a period of 14 years, Werner played a key role in growing BIOTRONIK from an early stage company to a global provider of medical devices for use in cardiology and cardiac surgery. Following spells as General Manager of Chiron Adatomed and VP of Marketing and Sales for Medtronic Europe, Middle East and Africa, Werner returned to BIOTRONIK in 2001 to become Managing Director, further developing the Company’s market expansion to become Europe’s largest privately-held medical device company in the cardiovascular arena. Werner holds or held several board positions, e. g. as a Member of the Board of Directors and Treasurer at EUCOMED (European Association of Medical Technology Manufacturers representing > 4.500 business entities), as a Non-Executive Director at ILIKA PLC, (IKA.L; Fast-tracking Material Discovery for the energy, electronics and biomedical sectors).


Thom Rasche
Partner, Earlybird

Thom joined Earlybird as a Venture Partner in 2003 and was promoted to Partner in 2006.

Thom has more than 11 years experience as investor. Further, he is a seasoned executive in the medical device and diagnostic sectors with over 25 years of operational experience. Since he joined Earlybird, Thom has been responsible for the medical device portfolio and new investments in this area. He has successfully led various financing rounds in both European and US based companies. He is an observing board member of Hemoteq AG (Aachen, Germany) and is currently on the board of EBS Technologies GmbH (Berlin) and Miracor Medical Systems GmbH (Vienna). Additionally Thom was a board member of BMEYE B.V. (Amsterdam), which was sold to Edwards Lifescience Corporation in 2012 and of Zonare Medical Systems, Inc. (Mountain View, CA), which was bought by Mindray Medical International Ltd in 2013. Thom has also been an observer at Calypso Medical Technologies Inc, (Seattle, WA) which was sold to Varian Medical Systems Inc. in 2011.

Before joining Earlybird, Thom was the Managing Director for Ethicon Endo-Surgery, a Johnson & Johnson company and was responsible for growing the company to be the market leader of minimal invasive surgery in Germany.

Prior to Ethicon, Thom was the Vice President Europe for Critikon, the inventor of non-invasive automated blood pressure monitoring where he was responsible for the European organization and the European Development Centre in Wales.

Thom has also held various senior marketing and sales positions with Johnson & Johnson in Europe and the US. Thom Rasche holds a Degree as Diplom Kaufmann (MBA equivalent) from the University of Applied Sciences in Lüneburg, Germany, specializing in marketing and human resource management.

Frank Kenny
Founder, Delta Partners

Frank Kenny founded Delta Partners in 1994, having previously worked in the VC industry with Burr, Egan, Deleage & Co. in Boston from 1983 to 1993. He was on the Board of many private technology companies in the U.S.A. and was on two NASDAQ Boards, Abacus Direct Corporation and Vivid Technologies Inc. from 1989 to 1999.
Frank currently serves on a number of private Boards including Advanced Surgical Concepts, Glysure, Miracor Medical Systems, and Neoss.
Frank holds a B. Comm. and M. Econ. Sc. from University College Dublin and an MBA from University of Chicago.


Hubertus Leonhardt
Managing Partner, SHS

Hubertus is managing partner of the German medical device investor SHS (www.shs-capital.eu). SHS is a sector specialist in medical devices and diagnostics and is focused on investments in Germany, Austria and Switzerland. The investment in Miracor has been completed out of the third fund generation. Currently SHS invests into new investments out of their 125m SHS IV fund. SHS portfolio companies include e.g. in Phenox, SIS Medical and AMW. Hubertus is in the venture capital industry since 1997, since then he has been responsible for several life science investments and exits. He has a degree in business management from Duale Hochschule, Mannheim, Baden Württemberg and post graduate qualifications as tax advisor and Chartered Financial Analyst. Previous to SHS he served as corporate finance project leader with the Frankfurt office of Arthur Andersen.


Patrick Burgermeister
Partner, BioMedPartners

Patrick has a strong operational background in Venture Capital, pharma, banking and medtech. He joined BioMedPartners in 2006 coming from Novartis where he was Senior Portfolio Manager of project management. There, he was responsible for the evaluation and prioritization of development projects from preclinical to registration stage.

Prior to Novartis, he was Senior Financial Analyst responsible for the European Biotech and Pharma sector at Zürcher Kantonalbank. In addition, he served as advisor to the healthcare fund Pharma Vision. Before that, he worked as strategic planning manager at Jomed AG (now Abbott Vascular).

Recently, Patrick headed the business development at Apeiron Biologics (Vienna, Austria) where he was instrumental in several licensing deals. He also served as chairman of a dermatology startup and is board member of the business angel club BioBAC.

Patrick holds a Master degree in Molecular Biology from the University of Basel (Biozentrum), a Master degree in Business Administration from the University of St. Gallen (HSG) and a degree as Chartered Financial Analyst (CFA).


Ralf Kunzmann
CEO, aws Founders Fund

Ralf is Managing Director of aws Fondsmanagement GmbH and CEO of aws Founders Fund (aws Gründerfonds), Austria’s most active Venture Capital Fund. Before joining aws in 2013 he was many years responsible for the international private equity activities of UniCredit Bank Austria Group and held numerous operational management functions as Managing Director and CFO at portfolio companies. Prior to that, he worked with KPMG in financial advisory services with specialization in corporate finance. After completing his studies in business administration, Ralf started his career in the healthcare industry in Investment Controlling and Corporate Development. Ralf is lecturer and author of numerous publications in the field of business acquisition.

Magnus Holm
Venture Partner, Peppermint VenturePartners

Magnus has been part of the Peppermint´s investment team since 2012 as a Venture Partner.

Magnus has  many years of operational experience in various executive positions in the medical technology industry, with focus on innovative diagnostic and therapeutic technologies in the cardiovascular area. In addition to development and clinical adoption of medical products, his experience include business development, business management and commercial operations.

As General Manager for companies such as Biosense Webster, EMEA and Stereotaxis Inc. (USA) Magnus has made a decisive contribution to the introduction of new innovative products and technologies that quickly have established themselves in clinical routines in the field of interventional cardiology and electrophysiology (3-D electro-anatomical mapping and treatment of cardiac arrhythmias, drug-eluting stents and robotic control of interventional therapeutic heart catheters).

Besides his role as Venture Partner at Peppermint, Magnus is also a board member of Personal MedSystems GmbH in Germany and CathVision Aps in Denmark, as well as having operational roles in some young medtech companies (Spectrum Dynamics Inc., Itamar Medical Inc., MD Medical Devices Consulting SAS).

Magnus holds a Master of Science Degree in Biomedical Engineering from University of Linköping (Sweden) and a PhD in Clinical Cardiology from the University of Lund (Sweden).

Prof. Dr. Dr. Werner Mohl
Medical University of Vienna, Austria

Professor Werner Mohl is the innovator of the PiCSO® concept and a long term academic surgeon at the Medical University of Vienna. Active in patient care, teaching and research in all perspectives of heart diseases including coronary hemodynamics, cardiac regeneration and cardioprotection, he also serves as advisor on a consulting basis for Miracor. He holds a medical degree and a PhD from the University of Vienna, Austria.